📗 Cite This Artifact
📖
NLRP3 Inflammasome Pathway in Alzheimer's Disease
active
wiki page
Created: 2026-04-02T07:19:49
By: crosslink-migration
Quality:
50%
✓ SciDEX
ID: wiki-mechanisms-nlrp3-inflammasome-ad-pa
📖 Wiki Page
mechanism1459 wordssynced 2026-04-02
NLRP3 Inflammasome Pathway in Alzheimer's Disease
The NLRP3 inflammasome is a critical innate immune sensor that drives neuroinflammation in Alzheimer's disease. Its activation by Aβ and other DAMPs creates a self-perpetuating inflammatory loop that accelerates neurodegeneration[Heneka MT 2013, NLRP3 is activated in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/23376256/)[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/).
Activation Triggers in AD
Primary Activators
- Amyloid-beta plaques: Direct NLRP3 activation via crystalline structure recognition[Halle A 2008, The NLRP3 inflammasome is activated by amyloid-β](https://pubmed.ncbi.nlm.nih.gov/18695076/)
- Aβ oligomers: Cellular uptake triggers lysosomal rupture and inflammasome assembly[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
- ATP release: From damaged neurons activates P2X7 receptors leading to NLRP3 activation[Zhang Y 2019, P2X7 receptor mediates NLRP3 activation in AD microglia](https://pubmed.ncbi.nlm.nih.gov/31740982/)
- Oxidative stress: ROS-mediated thioredoxin oxidation releases NLRP3 inhibition[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
- Lipid peroxidation: Products such as 4-HNE activate NLRP3[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
Molecular Cascade
...
NLRP3 Inflammasome Pathway in Alzheimer's Disease
The NLRP3 inflammasome is a critical innate immune sensor that drives neuroinflammation in Alzheimer's disease. Its activation by Aβ and other DAMPs creates a self-perpetuating inflammatory loop that accelerates neurodegeneration[Heneka MT 2013, NLRP3 is activated in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/23376256/)[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/).
Activation Triggers in AD
Primary Activators
- Amyloid-beta plaques: Direct NLRP3 activation via crystalline structure recognition[Halle A 2008, The NLRP3 inflammasome is activated by amyloid-β](https://pubmed.ncbi.nlm.nih.gov/18695076/)
- Aβ oligomers: Cellular uptake triggers lysosomal rupture and inflammasome assembly[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
- ATP release: From damaged neurons activates P2X7 receptors leading to NLRP3 activation[Zhang Y 2019, P2X7 receptor mediates NLRP3 activation in AD microglia](https://pubmed.ncbi.nlm.nih.gov/31740982/)
- Oxidative stress: ROS-mediated thioredoxin oxidation releases NLRP3 inhibition[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
- Lipid peroxidation: Products such as 4-HNE activate NLRP3[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
Molecular Cascade
Mermaid diagram (expand to render)
Downstream Effects
Interleukin-1β Effects
- Promotes tau phosphorylation via MAPK activation[Ghosh S 2013, IL-1β accelerates tau pathology through MAPK activation](https://pubmed.ncbi.nlm.nih.gov/24140361/)
- Enhances microglial phagocytosis but impairs Aβ clearance[Yin J 2019, NLRP3 promotes Aβ clearance via autophagy](https://pubmed.ncbi.nlm.nih.gov/31169807/)
- Drives synaptic dysfunction through IL-1R1 signaling[Lai M 2016, IL-1β and synaptic plasticity in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/26876401/)
- Promotes chronic inflammation in surrounding cells[Nicoll JA 2019, IL-1β and the progression of AD pathology](https://pubmed.ncbi.nlm.nih.gov/31068590/)
Interleukin-18 Effects
- Amplifies IFN-γ production from T cells[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
- Contributes to blood-brain barrier breakdown[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
- Enhances excitotoxicity through glutamate receptor modulation[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
ASC Specks
- Released ASC specks act as "inflammasome particles"[Venegas C 2017, Microglia-derived ASC specks accelerate Aβ pathology in AD](https://pubmed.ncbi.nlm.nih.gov/28392263/)
- Propagate NLRP3 activation to distant cells[Kumar A 2024, ASC specks propagate inflammasome activation in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38147098/)
- Serve as nuclei for Aβ aggregation[Venegas C 2017, Microglia-derived ASC specks accelerate Aβ pathology in AD](https://pubmed.ncbi.nlm.nih.gov/28392263/)
- Persist in brain tissue as chronic inflammatory foci[Venegas C 2017, Microglia-derived ASC specks accelerate Aβ pathology in AD](https://pubmed.ncbi.nlm.nih.gov/28392263/)
Therapeutic Targets
Inhibitors
- MCC950: Potent NLRP3 inhibitor; shows efficacy in AD models[Coll RC 2015, MCC950 is a potent and selective NLRP3 inhibitor](https://pubmed.ncbi.nlm.nih.gov/26504059/)
- Dapansutrile (OLT1177): Oral NLRP3 inhibitor in clinical trials[Marchetti C 2018, OLT1177 (dapansutrile) reduces neuroinflammation in AD models](https://pubmed.ncbi.nlm.nih.gov/30127443/)
- CRID3: Specific NLRP3 inhibitor reducing neuroinflammation[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
Downstream Blockers
- Anakinra: IL-1 receptor antagonist[Ridker PM 2017, Canakinumab reduces cardiovascular events](https://pubmed.ncbi.nlm.nih.gov/28936040/)
- Canakinumab: Anti-IL-1β antibody[Ridker PM 2017, Canakinumab reduces cardiovascular events](https://pubmed.ncbi.nlm.nih.gov/28936040/)
- Caspase-1 inhibitors: VX-765, prenalbastat[Song L 2019, Caspase-1 inhibition attenuates Aβ-induced neuronal death](https://pubmed.ncbi.nlm.nih.gov/30829574/)
Natural Compounds
- Curcumin, resveratrol, omega-3 fatty acids show partial NLRP3 inhibition[Xu HY 2021, Targeting NLRP3 inflammasome in AD: therapeutic strategies](https://pubmed.ncbi.nlm.nih.gov/34048641/)
NLRP3 Inhibitors in Clinical Trials for AD
Current Clinical Landscape
While no NLRP3-targeted therapy has yet received regulatory approval for AD, several compounds are in various stages of clinical development:
MCC950 and Derivatives:
- MCC950, a potent NLRP3 inhibitor originally discovered for cryopyrin-associated periodic syndrome (CAPS), has demonstrated neuroprotective effects in multiple AD mouse models[Coll RC 2015, MCC950 is a potent and selective NLRP3 inhibitor](https://pubmed.ncbi.nlm.nih.gov/26504059/)
- Preclinical studies show reduced amyloid plaque burden, improved cognitive performance, and decreased microglial activation
- Derivatives with improved blood-brain barrier penetration are being developed by several pharmaceutical companies[Danziger C 2022, NLRP3 targeting in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/35989321/)
- Oral β-sulfonyl nitrile compound that selectively inhibits NLRP3
- Currently in Phase II clinical trials for cardiovascular inflammatory conditions
- AD-focused trials are being planned based on promising neuroinflammation data from AD models[Marchetti C 2018, OLT1177 (dapansutrile) reduces neuroinflammation in AD models](https://pubmed.ncbi.nlm.nih.gov/30127443/)
- Canakinumab: Anti-IL-1β monoclonal antibody approved for CAPS and Still's disease; being repurposed for AD[Ridker PM 2017, Canakinumab reduces cardiovascular events](https://pubmed.ncbi.nlm.nih.gov/28936040/)
- Anakinra: IL-1 receptor antagonist with a favorable safety profile; completed Phase I/II trials in AD
- The CANTOS trial demonstrated that IL-1β inhibition reduces cardiovascular events, supporting the rationale for AD trials[Ridker PM 2017, Canakinumab reduces cardiovascular events](https://pubmed.ncbi.nlm.nih.gov/28936040/)
Challenges in Clinical Translation
- Blood-brain barrier penetration: NLRP3 inhibitors must cross the BBB at sufficient concentrations
- Timing of intervention: NLRP3 activation may be most critical in early disease stages
- Biomarker development: Need for PET ligands or fluid biomarkers to monitor target engagement
- Combination approaches: NLRP3 inhibition may be most effective when combined with anti-amyloid or anti-tau strategies
Microglial Phenotype Switching
NLRP3 and Microglial Polarization
NLRP3 activation is intimately linked to microglial phenotypic states in AD:
Pro-inflammatory (M1-like) State:
- NLRP3 activation drives microglial transition to a chronic pro-inflammatory state
- Characterized by elevated IL-1β, IL-6, TNF-α, and reactive oxygen species production
- This state impairs the microglial's ability to perform beneficial functions like Aβ clearance[Yin J 2019, NLRP3 promotes Aβ clearance via autophagy](https://pubmed.ncbi.nlm.nih.gov/31169807/)
- NLRP3 contributes to DAM formation in AD
- DAM exhibit increased phagocytic activity but reduced Aβ clearance efficiency
- NLRP3-mediated inflammation disrupts proper lysosomal function[Cai Y 2021, NLRP3 inflammasome mediates Aβ-induced neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/34048641/)
- TREM2 signaling can either promote or inhibit NLRP3 activation depending on context
- TREM2 deficiency exacerbates NLRP3-mediated inflammation
- Combined TREM2 activation and NLRP3 inhibition may represent a promising therapeutic strategy
- [TREM2 Microglial Pathway in AD](/mechanisms/trem2-microglia-pathway-alzheimers)
Phenotype Switching Mechanisms
Epigenetic Regulation:
- NLRP3 promoter demethylation in AD microglia promotes persistent activation
- Histone acetylation at NLRP3 locus enhances transcription
- HDAC inhibitors show potential for modulating NLRP3 expression
- NLRP3-activated microglia shift toward glycolytic metabolism
- This metabolic state reinforces the inflammatory phenotype
- Targeting glycolysis may indirectly suppress NLRP3 activation
- Reprogramming strategies: Small molecules and natural compounds that shift microglia toward an anti-inflammatory phenotype
- TREM2 modulation: Enhancing TREM2 signaling while inhibiting NLRP3 may restore proper microglial function
- CSF1R inhibition: Blocking microglial proliferation while preserving homeostatic microglia
Cross-Links to TREM2 and Tau Pathology
NLRP3-TREM2-Tau Axis
Mermaid diagram (expand to render)
TREM2-Mediated Effects on NLRP3
- TREM2 signaling: Modulates microglial inflammatory responses; loss-of-function variants increase AD risk
- TREM2-SYK axis: Downstream signaling can either amplify or suppress NLRP3 depending on ligand engagement
- TREM2 and ASC: TREM2 influences ASC speck formation and release
- See: [TREM2 Signaling in AD](/mechanisms/trem2-signaling)
NLRP3 and Tau Pathology
Mechanistic Links:
- IL-1β promotes tau hyperphosphorylation via MAPK and CDK5 pathways[Ghosh S 2013, IL-1β accelerates tau pathology through MAPK activation](https://pubmed.ncbi.nlm.nih.gov/24140361/)
- Caspase-1 can directly cleave tau, generating aggregation-prone fragments[Wang S 2019, Caspase-1 cleaves tau and promotes neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/30858568/)
- NLRP3 activation in microglia drives tau propagation through exosome release
- ASC specks can serve as templates for tau aggregation[Stancu IC 2019, NLRP3 inflammasome drives tau pathology](https://pubmed.ncbi.nlm.nih.gov/30944043/)
- NLRP3 knockout mice show reduced tau pathology
- MCC950 treatment decreases tau phosphorylation
- IL-1β infusion accelerates tau spread
- Combined anti-amyloid and anti-NLRP3 strategies may provide synergistic benefits
- Targeting IL-1β may break the NLRP3-tau vicious cycle
- [Tau Pathology Mechanisms](/mechanisms/neurofibrillary-tangles)
Cross-Links
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
- [Microglia Pathway in AD](/mechanisms/ad-neuroinflammation-microglia-pathway)
- [TREM2 Signaling](/mechanisms/trem2-signaling)
- [Pyroptosis in Neurodegeneration](/mechanisms/pyroptosis-neurodegeneration)
References
Related Entities
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-nlrp3-inflammasome-ad-pathway |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-eacba296edb0 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-nlrp3-inflammasome-ad-pathway'} |
| _schema_version | 1 |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
586
Outgoing
620
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
1 nodes, 0 edges
No provenance edges found
This artifact has no version history yet.
Linked Artifacts (739)
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-nlrp3-inflammasome-ad-pathway?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[NLRP3 Inflammasome Pathway in Alzheimer's Disease](http://scidex.ai/artifact/wiki-mechanisms-nlrp3-inflammasome-ad-pathway)
Direct URL
http://scidex.ai/artifact/wiki-mechanisms-nlrp3-inflammasome-ad-pathway
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.